Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference

Audio By Carbonatix

BOTHELL, Wash.--(BUSINESS WIRE)--Jan 6, 2026--

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST.

Interested parties can access a live audio webcast of the presentation via the Investor Relations section of Immunome’s website at www.immunome.com. A replay webcast will be available for approximately 30 days following the live presentation.

About Immunome, Inc.

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets. For more information, visit www.immunome.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260106254447/en/

CONTACT: Investor Contact

Max Rosett

Chief Financial Officer

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA WASHINGTON

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: Immunome, Inc.

Copyright Business Wire 2026.

PUB: 01/06/2026 08:00 AM/DISC: 01/06/2026 08:00 AM

http://www.businesswire.com/news/home/20260106254447/en